Hello, everyone, and how are you today? We are doing just fine, thank you, now that our shortest person has been deposited at the local schoolhouse and our official mascot has trotted off to a nearby corner for a morning snooze. This leaves us to the task at hand which, of course, involves foraging for interesting items. So please join us as we fire up the trusty coffee kettle, concoct another cup of stimulation — chocolate cherry decadence awaits — and dig in for another busy day. Hope all goes well and you conquer the world …

Purdue Pharma reached a tentative deal with about half the states and thousands of local governments over its role in the opioid crisis, but criticism by several state attorneys general clouded prospects for an end to litigation against the company and the family that owns it, the Associated Press reports. Arizona Attorney General Mark Brnovich said the deal included more money from the Sackler family, which had become a sticking point during the recent talks. Purdue will pay up to $12 billion over time and the Sacklers will give up control of Purdue.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Concerning the FTC estimate of the cost of pay to delay, let us consider this item from the American Academy of Actuaries:
    “In 2016, the U.S. spent $3,337 billion, [ i.e. $3.3 Trillion+] or 17.9 percent of the gross domestic product (GDP), on national health expenditures, of which $329 billion was spent on prescription drugs.2
    So the $3.2 Billion USD estimated savings would be just under one penny on the dollar spent. Well, one supposes a penny saved, etc, but these numbers argue it is hardly worth some of the ‘storm und drang’ over this subject.
    Additional thought – how much is ‘double counted’ in the estimates of the impact of biosimilars (or lack thereof?)

    • Dear Observer,

      Assuming the math is correct, I get your point. Even so, as you note, a penny is saved… And for some folks, pennies add up more quickly than for others.

      Moreover, there are legal principles involved that can be extended and pursued in the interest of public health policy.

      No reason, I can think of, to turn a blind eye.

      All best,
      ed at pharmalot

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy